Does the media refer more to ORIC or CRBU?

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 2 articles in the media. Caribou Biosciences' average media sentiment score of 0.51 beat Oric Pharmaceuticals' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRBU or SANA?

In the previous week, Sana Biotechnology had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.51 beat Sana Biotechnology's score of 0.19 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CRBU or PHAR?

In the previous week, Pharming Group had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Pharming Group and 2 mentions for Caribou Biosciences. Pharming Group's average media sentiment score of 0.66 beat Caribou Biosciences' score of 0.51 indicating that Pharming Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRBU or KURA?

In the previous week, Kura Oncology had 10 more articles in the media than Caribou Biosciences. MarketBeat recorded 12 mentions for Kura Oncology and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.51 beat Kura Oncology's score of -0.16 indicating that Caribou Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Caribou Biosciences (CRBU) Competitors

$1.92 -0.15 (-7.25%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$1.97 +0.05 (+2.60%)

As of 06/5/2026 07:45 PM Eastern

Compare

CRBU vs. ORIC, SANA, PHAR, KURA, and ABUS

Should you buy Caribou Biosciences stock or one of its competitors? MarketBeat compares Caribou Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Caribou Biosciences include Oric Pharmaceuticals (ORIC), Sana Biotechnology (SANA), Pharming Group (PHAR), Kura Oncology (KURA), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry.

How does Caribou Biosciences compare to Oric Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Caribou Biosciences (NASDAQ:CRBU) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Oric Pharmaceuticals has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Oric Pharmaceuticals' return on equity of -35.33% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%

Oric Pharmaceuticals currently has a consensus target price of $19.36, suggesting a potential upside of 158.18%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 351.39%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Oric Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

95.1% of Oric Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are owned by institutional investors. 5.7% of Oric Pharmaceuticals shares are owned by insiders. Comparatively, 8.5% of Caribou Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 2 articles in the media. Caribou Biosciences' average media sentiment score of 0.51 beat Oric Pharmaceuticals' score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Caribou Biosciences has a beta of 2.33, suggesting that its stock price is 133% more volatile than the broader market.

Oric Pharmaceuticals has higher earnings, but lower revenue than Caribou Biosciences. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Caribou Biosciences	$11.16M	17.06	-$148.12M	-$1.42	N/A

Summary

Caribou Biosciences beats Oric Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Caribou Biosciences compare to Sana Biotechnology?

Caribou Biosciences (NASDAQ:CRBU) and Sana Biotechnology (NASDAQ:SANA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Sana Biotechnology has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Sana Biotechnology	N/A	-108.01%	-40.68%

Caribou Biosciences has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 8.5% of Caribou Biosciences shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Caribou Biosciences has higher revenue and earnings than Sana Biotechnology. Sana Biotechnology is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	17.06	-$148.12M	-$1.42	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

In the previous week, Sana Biotechnology had 2 more articles in the media than Caribou Biosciences. MarketBeat recorded 4 mentions for Sana Biotechnology and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.51 beat Sana Biotechnology's score of 0.19 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Caribou Biosciences currently has a consensus price target of $8.67, suggesting a potential upside of 351.39%. Sana Biotechnology has a consensus price target of $9.50, suggesting a potential upside of 254.48%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Caribou Biosciences is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Caribou Biosciences beats Sana Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Caribou Biosciences compare to Pharming Group?

Caribou Biosciences (NASDAQ:CRBU) and Pharming Group (NASDAQ:PHAR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

Pharming Group has a net margin of 3.30% compared to Caribou Biosciences' net margin of -1,189.14%. Pharming Group's return on equity of 4.64% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Pharming Group	3.30%	4.64%	2.55%

Caribou Biosciences currently has a consensus target price of $8.67, suggesting a potential upside of 351.39%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 203.87%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Caribou Biosciences is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Pharming Group had 1 more articles in the media than Caribou Biosciences. MarketBeat recorded 3 mentions for Pharming Group and 2 mentions for Caribou Biosciences. Pharming Group's average media sentiment score of 0.66 beat Caribou Biosciences' score of 0.51 indicating that Pharming Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	17.06	-$148.12M	-$1.42	N/A
Pharming Group	$376.13M	2.37	$2.85M	$0.16	78.84

Caribou Biosciences has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, suggesting that its share price is 104% less volatile than the broader market.

Summary

Pharming Group beats Caribou Biosciences on 10 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Kura Oncology?

Caribou Biosciences (NASDAQ:CRBU) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Kura Oncology has a net margin of -411.19% compared to Caribou Biosciences' net margin of -1,189.14%. Caribou Biosciences' return on equity of -84.17% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Kura Oncology	-411.19%	-141.95%	-43.28%

In the previous week, Kura Oncology had 10 more articles in the media than Caribou Biosciences. MarketBeat recorded 12 mentions for Kura Oncology and 2 mentions for Caribou Biosciences. Caribou Biosciences' average media sentiment score of 0.51 beat Kura Oncology's score of -0.16 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Caribou Biosciences has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	17.06	-$148.12M	-$1.42	N/A
Kura Oncology	$67.48M	11.50	-$278.67M	-$3.35	N/A

77.5% of Caribou Biosciences shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Caribou Biosciences has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Caribou Biosciences presently has a consensus target price of $8.67, indicating a potential upside of 351.39%. Kura Oncology has a consensus target price of $25.58, indicating a potential upside of 192.72%. Given Caribou Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Caribou Biosciences is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Summary

Caribou Biosciences beats Kura Oncology on 12 of the 17 factors compared between the two stocks.

How does Caribou Biosciences compare to Arbutus Biopharma?

Caribou Biosciences (NASDAQ:CRBU) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, media sentiment, earnings, dividends and profitability.

Caribou Biosciences has a beta of 2.33, indicating that its share price is 133% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

Arbutus Biopharma has a net margin of 83.95% compared to Caribou Biosciences' net margin of -1,189.14%. Arbutus Biopharma's return on equity of 129.32% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,189.14%	-84.17%	-60.51%
Arbutus Biopharma	83.95%	129.32%	112.24%

In the previous week, Caribou Biosciences had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Caribou Biosciences and 0 mentions for Arbutus Biopharma. Caribou Biosciences' average media sentiment score of 0.51 beat Arbutus Biopharma's score of 0.00 indicating that Caribou Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Caribou Biosciences	Positive
Arbutus Biopharma	Neutral

Arbutus Biopharma has higher revenue and earnings than Caribou Biosciences. Caribou Biosciences is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	17.06	-$148.12M	-$1.42	N/A
Arbutus Biopharma	$14.08M	59.63	-$33.50M	$0.83	5.12

Caribou Biosciences currently has a consensus price target of $8.67, indicating a potential upside of 351.39%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 17.65%. Given Caribou Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Caribou Biosciences is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Arbutus Biopharma beats Caribou Biosciences on 9 of the 17 factors compared between the two stocks.

Get Caribou Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBU vs. The Competition

Export

Metric	Caribou Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$190.43M	$3.34B	$6.66B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.55%
P/E Ratio	-1.35	10.33	20.31	21.86
Price / Sales	17.06	300.34	516.18	112.47
Price / Cash	N/A	51.45	26.99	37.22
Price / Book	1.47	7.97	10.24	6.66
Net Income	-$148.12M	$23.89M	$3.57B	$337.55M
7 Day Performance	-18.64%	-6.96%	-1.28%	-2.52%
1 Month Performance	2.13%	-2.80%	1.38%	-0.03%
1 Year Performance	52.38%	36.80%	23.93%	25.34%

Caribou Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBU Caribou Biosciences	2.0939 of 5 stars	$1.92 -7.2%	$8.67 +351.4%	+52.4%	$190.43M	$11.16M	N/A	100
ORIC Oric Pharmaceuticals	1.9564 of 5 stars	$8.98 +6.3%	$19.36 +115.6%	-19.5%	$929.59M	N/A	N/A	80	High Trading Volume
SANA Sana Biotechnology	3.439 of 5 stars	$3.21 -2.7%	$9.50 +196.0%	-5.6%	$918.36M	N/A	N/A	380	News Coverage Analyst Downgrade
PHAR Pharming Group	3.8968 of 5 stars	$13.10 +0.8%	$38.33 +192.6%	+5.6%	$917.42M	$376.13M	81.88	280	News Coverage Gap Down
KURA Kura Oncology	2.1518 of 5 stars	$9.03 -11.5%	$25.90 +186.8%	+29.9%	$905.50M	$71.64M	N/A	130	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBU) was last updated on 6/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Caribou Biosciences (CRBU) Competitors

CRBU vs. ORIC, SANA, PHAR, KURA, and ABUS

How does Caribou Biosciences compare to Oric Pharmaceuticals?

Summary

How does Caribou Biosciences compare to Sana Biotechnology?

Summary

How does Caribou Biosciences compare to Pharming Group?

Summary

How does Caribou Biosciences compare to Kura Oncology?

Summary

How does Caribou Biosciences compare to Arbutus Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Caribou Biosciences (CRBU) Competitors

CRBU vs. ORIC, SANA, PHAR, KURA, and ABUS

How does Caribou Biosciences compare to Oric Pharmaceuticals?

Is ORIC or CRBU more profitable?

Do analysts recommend ORIC or CRBU?

Do institutionals & insiders hold more shares of ORIC or CRBU?

Does the media refer more to ORIC or CRBU?

Which has more risk and volatility, ORIC or CRBU?

Which has stronger valuation and earnings, ORIC or CRBU?

Summary

How does Caribou Biosciences compare to Sana Biotechnology?

Is CRBU or SANA more profitable?

Which has more risk and volatility, CRBU or SANA?

Do institutionals and insiders hold more shares of CRBU or SANA?

Which has stronger earnings and valuation, CRBU or SANA?

Does the media refer more to CRBU or SANA?

Do analysts prefer CRBU or SANA?

Summary

How does Caribou Biosciences compare to Pharming Group?

Is CRBU or PHAR more profitable?

Do analysts rate CRBU or PHAR?

Do institutionals & insiders have more ownership in CRBU or PHAR?

Does the media refer more to CRBU or PHAR?

Which has better earnings & valuation, CRBU or PHAR?

Which has more risk and volatility, CRBU or PHAR?

Summary

How does Caribou Biosciences compare to Kura Oncology?

Is CRBU or KURA more profitable?

Does the media favor CRBU or KURA?

Which has preferable valuation & earnings, CRBU or KURA?

Do insiders and institutionals believe in CRBU or KURA?

Which has more volatility and risk, CRBU or KURA?

Do analysts prefer CRBU or KURA?

Summary

How does Caribou Biosciences compare to Arbutus Biopharma?

Which has more volatility & risk, CRBU or ABUS?

Is CRBU or ABUS more profitable?

Does the media favor CRBU or ABUS?

Which has better earnings and valuation, CRBU or ABUS?

Do analysts prefer CRBU or ABUS?

Do institutionals & insiders believe in CRBU or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBU vs. The Competition

Caribou Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools